NEO upgraded to Buy by BTIG analyst Mark Massaro with $28 target, up from Neutral; stock at $19.13, implying 46% upside.
Key data as of 20 Oct 2026
NEO upgraded to Buy by BTIG analyst Mark Massaro with $28 target, up from Neutral; stock at $19.13, implying 46% upside.
NeoGenomics is delivering its earnings result tonight with the sharpest short position in months sitting opposite a Street that just moved materially higher on its targets. The positioning story is the most charged it…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for NEO — free to start on ORTEX.
Sign up for free →Open NEO on ORTEX